Abstract
Non-alcoholic fatty liver disease (NAFLD) is often associated with features of the metabolic syndrome, carrying an increased risk to develop non-alcoholic steatohepatitis (NASH), the inflammatory form of liver steatosis. Epidemiological data confirm that obesity, diabetes, hypertension and hyperlipidemia are frequently found in NAFLD and worsen its prognosis because of increased risk of fibrotic evolution, eventually leading to liver cirrhosis. Recent studies confirm the close relationship between the metabolic syndrome and liver steatosis, and further support the detrimental role of oxidative stress and lipid peroxidation, which are pathophysiological processes present in both conditions. Novel diagnostic tools and life style modifications together with targeted therapeutic actions are urgently needed for the management of liver dysfunction in course of metabolic syndrome.
Keywords: Metabolic syndrome, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, breath test
Current Pharmaceutical Design
Title: Non-Alcoholic Fatty Liver Disease in the Metabolic Syndrome
Volume: 13 Issue: 21
Author(s): Giuseppe Palasciano, Antonio Moschetta, Vincenzo O. Palmieri, Ignazio Grattagliano, Gianluca Iacobellis and Piero Portincasa
Affiliation:
Keywords: Metabolic syndrome, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, breath test
Abstract: Non-alcoholic fatty liver disease (NAFLD) is often associated with features of the metabolic syndrome, carrying an increased risk to develop non-alcoholic steatohepatitis (NASH), the inflammatory form of liver steatosis. Epidemiological data confirm that obesity, diabetes, hypertension and hyperlipidemia are frequently found in NAFLD and worsen its prognosis because of increased risk of fibrotic evolution, eventually leading to liver cirrhosis. Recent studies confirm the close relationship between the metabolic syndrome and liver steatosis, and further support the detrimental role of oxidative stress and lipid peroxidation, which are pathophysiological processes present in both conditions. Novel diagnostic tools and life style modifications together with targeted therapeutic actions are urgently needed for the management of liver dysfunction in course of metabolic syndrome.
Export Options
About this article
Cite this article as:
Giuseppe Palasciano , Antonio Moschetta , Vincenzo O. Palmieri , Ignazio Grattagliano , Gianluca Iacobellis and Piero Portincasa , Non-Alcoholic Fatty Liver Disease in the Metabolic Syndrome, Current Pharmaceutical Design 2007; 13 (21) . https://dx.doi.org/10.2174/138161207781039652
DOI https://dx.doi.org/10.2174/138161207781039652 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Adrenomedullin in Hypertension and Obesity
Current Hypertension Reviews Dysfunction of Pulmonary Vascular Endothelium in Chronic Obstructive Pulmonary Disease: Basic Considerations for Future Drug Development
Current Drug Metabolism Anti-VEGF Anticancer Drugs: Mind the Hypertension
Recent Advances in Cardiovascular Drug Discovery (Discontinued) The Role of Xanthine Oxidase Inhibitors in Patients with History of Stroke: A Systematic Review
Current Vascular Pharmacology Melatonin and Respiratory Diseases: A Review
Current Topics in Medicinal Chemistry Molecular Docking Study of a Series of Substituted Xanthone Derivatives as Novel COX-2 Inhibitors Targeting Prostaglandin Endoperoxide Synthase -2
Current Enzyme Inhibition Biological Mechanisms Linking Alzheimer's Disease and Type-2 Diabetes Mellitus
CNS & Neurological Disorders - Drug Targets miR-126 as a Therapeutic Agent for Diabetes Mellitus
Current Pharmaceutical Design NF-κB and Proteinuric Renal Disease
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Momordica balsamina: A Medicinal and Neutraceutical Plant for Health Care Management
Current Pharmaceutical Biotechnology Modulation of Aquaporins by Dietary Patterns and Plant Bioactive Compounds
Current Medicinal Chemistry Impact of Traditional Therapies and Biologics on Cardiovascular Diseases in Rheumatoid Arthritis
Current Vascular Pharmacology EDITORIAL [Hot Topic: Anti-Vascular Endothelial Growth Factor (VEGF) Treatment of Ophthalmic Conditions (Guest Editor: Michael W. Stewart)]
Current Drug Therapy Editorial from Guest Editor: Current Management of Sleep Apnea and Comorbidities
Current Respiratory Medicine Reviews Neuro-Psychological Pattern in Patients Suffering from Primitive Dilated Cardiomyopathy with Impairment in Executive Function
Current Neurovascular Research Carotid Intima Media Thickness and Beyond
Current Drug Targets - Cardiovascular & Hematological Disorders Lock Stock and Barrel of Wound Healing
Current Pharmaceutical Design Stress in Gastrointestinal Tract and Stable Gastric Pentadecapeptide BPC 157. Finally, do we have a Solution?
Current Pharmaceutical Design Hypertension - Current Natural Strategies to Lower Blood Pressure
Current Pharmaceutical Design Risk of Bleeding Related to Antithrombotic Treatment in Cardiovascular Disease
Current Pharmaceutical Design